Patient with disseminated malignant tumor of the pancreas. Application of liposomal irinotecan as a new option of palliative treatment Case report

Main Article Content

Bogumiła Galińska
Rafał Becht

Abstract

In palliative treatment of pancreatic neoplasms, chemotherapy regimens with gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, 5-fluorouracil or combinations of these drugs are used. The registration of liposomal irinotecan in the treatment of stage IV disease in patients with progression after gemcitabine creates new options for the treatment choice. The described case concerns a relatively young patient in whom the use of liposomal irinotecan in the registration indication turned out to be a safe and well-tolerated treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Galińska B, Becht R. Patient with disseminated malignant tumor of the pancreas. Application of liposomal irinotecan as a new option of palliative treatment. OncoReview [Internet]. 2021Jul.12 [cited 2021Dec.9];11(3(43):73-6. Available from: https://www.journalsmededu.pl/index.php/OncoReview/article/view/1518
Section
PERSONALIZED ONCOLOGY

References

1. Ducreux M, Cuhna A Sa, Caramella C et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 25(suppl 5): V56-V68.
2. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2019 r.
3. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.